ArticlePediatric nephrology (Berlin, Germany)2008
Rituximab therapy for juvenile-onset systemic lupus erythematosus.
Article in Pediatric nephrology (Berlin, Germany), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 5 syntheses or guidelines pooled it, 97 citations in OpenAlex.
- Safety and efficacy of biologics in childhood systemic lupus erythematosus: a critical systematic review.Clinical rheumatology · 2024Pooled it
- Rituximab for treating inhibitors in people with inherited severe hemophilia.The Cochrane database of systematic reviews · 2020Pooled it
- Efficacy and safety of rituximab for systemic lupus erythematosus treatment: a meta-analysis.African health sciences · 2020Pooled it
- Rituximab for treating inhibitors in people with inherited severe hemophilia.The Cochrane database of systematic reviews · 2017Pooled it
- Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysis.Journal of Zhejiang University. Science. B · 2012Pooled it
- Extrapolation of Adult Efficacy Data to Pediatric Systemic Lupus Erythematosus: Evaluating Similarities in Exposure-Response.Journal of clinical pharmacology · 2023Trial
- Combination therapy with steroids and mizoribine in juvenile SLE: a randomized controlled trial.Pediatric nephrology (Berlin, Germany) · 2010Trial
- Paediatric lupus nephritis: defining remission and the evolving therapeutic landscape.Pediatric nephrology (Berlin, Germany) · 2026Article
- Managing Lupus Nephritis in Children and Adolescents.Paediatric drugs · 2024Review
- Long-term outcomes with rituximab as add-on therapy in severe childhood-onset lupus nephritis.Pediatric nephrology (Berlin, Germany) · 2023Article
- Rituximab Biosimilar BCD020 Shows Superior Efficacy above Conventional Non-Biologics Treatment in Pediatric Lupus Nephritis: The Data of Retrospective Cohort Study.Biomedicines · 2023Article
- Altered frequency of peripheral B-cell subsets and their correlation with disease activity in patients with systemic lupus erythematosus: A comprehensive analysis.Journal of cellular and molecular medicine · 2020Article
- Combination therapy of rituximab and mycophenolate mofetil in childhood lupus nephritis.Pediatric nephrology (Berlin, Germany) · 2018Article
- Treatment of pediatric-onset lupus nephritis: a proposal of optimal therapy.Clinical and experimental nephrology · 2017Review
- Reviewing the recommendations for lupus in children.Current rheumatology reports · 2015Review
- Safety and efficacy of combined cyclophosphamide and rituximab treatment in recalcitrant childhood lupus.Rheumatology international · 2014Article
- A treatment algorithm for children with lupus nephritis to prevent developing renal failure.International journal of preventive medicine · 2014Review
- [B-cell targeted therapy for children and adolescents with rheumatic diseases].Zeitschrift fur Rheumatologie · 2013Article
- Three decades of progress in treating childhood-onset lupus nephritis.Clinical journal of the American Society of Nephrology : CJASN · 2011Article
- B cell depletion for autoimmune diseases in paediatric patients.Clinical rheumatology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rituximab (RTX), an anti-CD20 monoclonal antibody, has been proposed for use in the therapy of systemic lupus erythematosus (SLE). We present the initial long-term experience of the safety and efficacy of rituximab for treatment of SLE in children. Eighteen patients (mean age 14 +/- 3 years) with severe SLE were treated with rituximab after demonstrating resistance or toxicity to conventional regimens. There was a predominance of female (16/18) and ethnic African (13/18) patients. All had lupus nephritis [World Health Organization (WHO) classes 3-5] and systemic manifestations of vasculitis. Clinical disease activity of the SLE was scored with the SLE-disease activity index 2K (SLEDAI-2K). Patients were followed-up for an average of 3.0 +/- 1.3 years (range 0.5 to 4.8 years). B-cell depletion occurred within 2 weeks in all patients and persisted for up to 1 year in some. Clinical activity scores, double-stranded DNA (dsDNA) antibodies, renal function and proteinuria [urine protein to creatinine ratio (Upr/cr)] improved in 93% of the patients. Five patients required multiple courses of RTX for relapse, with B-cell repopulation. One died of infectious endocarditis related to severe immunosuppression. In conclusion, our data support the efficacy of rituximab as adjunctive treatment for SLE in children. Although rituximab was well tolerated by the majority of patients, randomized controlled trials are required to establish its long-term safety and efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.